New shot aims to stop mouth lesions before they become cancer
NCT ID NCT07620496
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a drug called CAN1012, which is injected directly into pre-cancerous mouth lesions. The goal is to see if it is safe and can activate the immune system to fight the abnormal cells. The study involves 36 adults with oral epithelial dysplasia who will receive the injection before their planned surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAN1012 (a drug injected into the lesion to activate the immune system)
What this could lead to
If successful, this could point toward a treatment that prevents oral dysplasia from turning into cancer, reducing the need for surgery.
What could go wrong
This is a very early, small phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to work in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL EPITHELIAL DYSPLASIA (OED) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••